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Abstract
Background: At present, there are no clinically reliable disease markers for chronic fatigue
syndrome. DNA chip microarray technology provides a method for examining the differential
expression of mRNA from a large number of genes. Our hypothesis was that a gene expression
signature, generated by microarray assays, could help identify genes which are dysregulated in
patients with post-infectious CFS and so help identify biomarkers for the condition.
Methods: Human genome-wide Affymetrix GeneChip arrays (39,000 transcripts derived from
33,000 gene sequences) were used to compare the levels of gene expression in the peripheral
blood mononuclear cells of male patients with post-infectious chronic fatigue (n = 8) and male
healthy control subjects (n = 7).
Results: Patients and healthy subjects differed significantly in the level of expression of 366 genes.
Analysis of the differentially expressed genes indicated functional implications in immune
modulation, oxidative stress and apoptosis. Prototype biomarkers were identified on the basis of
differential levels of gene expression and possible biological significance
Conclusion: Differential expression of key genes identified in this study offer an insight into the
possible mechanism of chronic fatigue following infection. The representative biomarkers identified
in this research appear promising as potential biomarkers for diagnosis and treatment.
Background
Persistent fatigue after infection is recognised and forms
part of a clinically-defined syndrome (chronic fatigue syn-
drome or CFS). CFS is a highly heterogeneous illness
which is characterised by the presence of new-onset, per-
sistent or relapsing fatigue of sufficient severity that inter-
feres with normal activity. Patients also report impaired
short-term memory and concentration, muscle pain and
post-exertional malaise [1]. The clinical incidence of CFS
in the population ranges from 0.23–2% and nearly 75%
of patients are female [2,3]. The cause and pathogenesis of
CFS are not understood and, to date, no standard labora-
tory test reliably distinguishes CFS patients from healthy
subjects. As a result, persistence of otherwise medically-
unexplained chronic fatigue often has been attributed to
psychological factors.
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In recent years, numerous microarray studies have been
undertaken in order to distinguish patients with chronic
fatigue from healthy controls. This subject has also been
covered extensively in a special 2006 issue of the journal
Pharmacogenomics. In this issue, several papers utilised
numerous multivariate projection methods, bioinformat-
ics, algorithms and computational analyses of microarray
data, in order to provide better discrimination of subjects
with unexplained chronic fatigue and CFS, from healthy
controls [4-7].
Although chronic fatigue is well recognised after certain
infections (for example, Lyme disease and Epstein-Barr
virus), CFS is not commonly considered to be due to per-
sistent infection. A preceding history of non-infection is
frequently reported and recent studies indicate other fac-
tors may be responsible for the symptoms of this condi-
tion [8,9]. As a result, few studies have specifically
addressed changes in gene expression in post-infectious
subjects [10,11].
We hypothesised that patients with persistent fatigue
developing after community-acquired infections are bio-
logically different from healthy subjects and this would be
reflected in a differential gene signature. Recent advances
in genome sequencing and automated chip manufacture
have made DNA chip or microarray technology readily
available [12]. This technology allows simultaneous dif-
ferential expression profiling from a large number of
genes in tissue samples of CFS patients and controls. A
previous study, using microarray technology encoding
1,764 genes and RNA from peripheral blood mononu-
clear cells (PBMC), demonstrated the utility of white
blood cells for gene expression profiling on an illness
without a known pathological lesion, such as CFS [13]. A
more recent microarray study utilising 9,522 genes con-
cluded that patients with CFS have reproducible altera-
tions in gene regulation [14]. In addition, a study of
exercise-responsive genes using a 3,800 oligonucleotide
microarray showed significant differences in membrane
ion transport genes in women with CFS, as compared to
control subjects [15].
In our study, we aimed to obtain a complete "gene signa-
ture" for non-psychiatric patients with post-infectious per-
sistent chronic fatigue. We excluded female subjects in
order to avoid confounding factors from the monthly
reproductive cycle. By using an Affymetrix GeneChip
Human Genome U133 double-chip set that contains
nearly 45,000 probe sets, representing 39,000 transcripts
derived from more than 33,000 human gene sequences,
most of the known human genome was encompassed in
this work.
Methods
Study subjects
All patients underwent full medical and neurological eval-
uation clinically and had appropriate investigations to
exclude alternative explanations for their symptoms. All
patients with CFS fulfilled the international research crite-
ria for diagnosis [1]. CFS patients and healthy subjects
were closely matched for age, ethnicity and for place of
residence in a common geographic area (central Scot-
land). Eight male patients aged between 18 and 54 years
(median 36 years) with well-characterised, post-infectious
CFS (median duration 4.5 years), after a documented his-
tory of viral or bacterial infections, were still independent,
not clinically anxious or depressed and not taking regular
medication were selected. Seven asymptomatic and phys-
ically active males aged between 22 and 58 years (median
34 years), with no recent history of infection, were used as
healthy controls. Female participants at this stage were
deliberately excluded to avoid confounding factors from
their reproductive cycles and contraception. Informed
consent and local ethical approval were obtained.
Specimens
Male patients with post-infectious CFS and normal
healthy controls underwent venous blood sample collec-
tion (prior to 11 am) in 2 × 5 ml EDTA tubes. PBMC were
isolated immediately and stored within 2 hours of sam-
pling. EDTA-treated whole blood was diluted 1:1 with
phosphate buffered saline (PBS). Two volumes of blood
were overlaid onto one volume Histopaque-1077 (Sigma)
and centrifuged at 20°C, 500 g for 30 min. The PBMC
interfaces were washed twice with PBS and the pellets
were re-suspended in PBS. Aliquots were counted and dry
pellets (2 × 105 cells) were stored under liquid nitrogen.
RNA preparation
Total RNA was isolated from PBMC pellets following the
detailed manufacturer's protocols in the Promega RNA-
gents Total Isolation System.
Microarray Assay
RNA quality was confirmed using an Agilent RNA BioAn-
alyzer 2100. The target samples were prepared following
GeneChip One-Cycle Target Labeling protocol (Affyme-
trix). All 15 samples were then hybridised to Affymetrix
GeneChip HG-U133A and HG-U133B arrays. The arrays
were washed and stained using Affymetrix protocols on
the Fluidics Station 400 and scanned on the Gene Array
Scanner 2500.
Analysis: Analysis
GCOS1.1.1 software (Affymetrix) was used to generate
raw data from scanned images. Data analysis was per-
formed using FunAlyse, an in-house built automatedBMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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pipeline in Sir Henry Wellcome Functional Genomics
Facility (SHWFGF), University of Glasgow.
This analysis consists of the Robust Multichip Average
(RMA) normalisation [16], followed by the identification
of differentially expressed genes using the Rank Products
(RP) method [17], performed for A and B chips separately.
Briefly, the RP method sorts Affymetrix probe-sets by geo-
metric mean of their ranks, calculated over all possible
between-chip comparisons contributing to the disease vs.
control comparison, where ranks are calculated after sort-
ing probe-sets by log fold-change between each CFS and
each control sample [17]. This method has been proven
superior to others in situations where compared condi-
tions are represented by small numbers of replicated sam-
ples [17-19]. Subsequently, the RP expression profiles for
chips A and B chips were merged and trimmed at the sig-
nificance cut-off of false discovery rate, FDR < 0.01 and
fold change, FC > 1.5. The fold-change is initially calcu-
lated as an antilog of a mean log fold-change over all pos-
sible between-chip comparisons contributing to the
disease vs. control comparison after RMA normalisation.
It is then corrected using a procedure to compensate for
RMA specific distortion of fold-change values [20].
The above RP-generated expression profile was then ana-
lysed with the Ingenuity Pathway Analysis (IPA) software
(Ingenuity® Systems, http://www.ingenuity.com) in order
to identify possible biological processes associated with
differentially expressed genes. The initial set of differen-
tially expressed, redundant Affymetrix probe-sets was first
mapped to Entrez Gene identifiers [21] and then submit-
ted to the IPA server. Here, each Entrez Gene identifier was
mapped to its corresponding object in the Ingenuity Path-
ways Knowledge Base (IPKB), which resulted in conver-
sion of the initial expression profile into a shorter dataset
of well-characterised, non-redundant "focus" genes. These
genes were then overlaid onto a global molecular network
developed from information contained in the IPKB and a
number of small networks (up to 35 genes in total) were
then algorithmically generated, based on their connectiv-
ity. Subsequently, for each network the genes associated
with biological functions were identified and Fisher's
exact test was then used to calculate p-values, determining
the probability that each biological function assigned to a
given network is due to chance alone. The whole dataset
of the "focus genes" was then analysed in order to identify
its most representative gene functional classes, as well as
the most representative canonical pathways. The "focus"
genes associated with biological functions were identified
and the Fisher's exact test was then used to calculate p-val-
ues determining the probability that each biological func-
tion assigned to the "focus" gene data-set is due to chance
alone. Similarly, the "focus" genes associated with canon-
ical pathways were identified but the significance of that
association was measured in two ways, (i) A ratio of the
number of genes from the dataset that map to a given
pathway, divided by the total number of genes that map
to that pathway, is displayed, and (ii) the Fisher's exact
test was used to calculate p-values determining the proba-
bility that the association between the genes in the dataset
and a given canonical pathway is explained by chance
alone. For all the above IPA analyses the Fisher exact test
p-values were converted to the score equal to -log(p-
value).
The data discussed in this publication have been depos-
ited in NCBI's Gene Expression Omnibus [22] and are
accessible through GEO Series accession number
GSE14577 http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE14577.
Validation of defensin-α1
An additional cohort of 10 patients with CFS and 10 age-
and sex-matched controls were recruited for Reverse Tran-
scription-Polymerase Chain Reaction (RT-PCR) and west-
ern blot assays, in order to verify the microarray data for
one of the putative biomarkers, defensin-α1.
RT-PCR
cDNA synthesis and PCR were performed as described
previously [23,24] and primers generated an amplified
PCR product of the expected size 288 bp. The defensin-α1
oligonucleotide primers used were:
sense 5'-CAAGAGCTGATGAGGTTGCT-3'
antisense 5'-GAAGGTACAGGAGTAATAGC-3'.
Western Blot
PBMC pellets were re-suspended in sample-reducing
buffer (1 ml glycerol, 0.5 ml β-mercaptoethanol, 3 ml
10% SDS, 1.25 ml 1 M Tris-HCl, pH 6.7) and boiled for 5
min. The cell lysates were loaded onto 10% PAGE gels,
each track equivalent to 2 × 105 PBMC. PAGE gels were
assessed for equal protein loading by coomassie blue
staining. The gels were then electrophoretically trans-
ferred onto PVDF membranes (BioRad), for 2 hours. Blots
were blocked with 10% normal goat serum for 30 min,
and then incubated for 2 hours at room temperature with
a monoclonal antibody to human neutrophil defensin
α1–3 (1:100, clone D21, HyCult Biotechnology, Nether-
lands), diluted in TBS/0.05% Tween-20. Proteins were
detected with a 1:1000 dilution of alkaline phosphatase-
conjugated goat anti-mouse IgG (Jackson Immunore-
search Laboratories, PA, USA) and protein bands were
detected using SIGMA FAST BCIP/NBT.
Results
Identification of differentially expressed genes
A number of genes were significantly over- or under-
expressed in CFS patients, as compared to healthy con-BMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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trols, in genome-wide microarray analysis. The Rank
Products analysis revealed that 413 Affymetrix probe-sets
were significantly up-regulated and 189 significantly
down-regulated (602 in total) in the CFS samples. Of the
significantly up-regulated probe-sets, 141 showed the
expression changed at least 2-fold and 20 at least 3-fold.
The corresponding numbers for the down regulated
probe-sets are 57 and 2, respectively.
IPA results
Annotating the above list of 602 differentially expressed
probe-sets with EntrezGene IDs and subsequent submis-
sion to the IPA server resulted in successful mapping of
the above probe-sets to 366 non-redundant "focus" genes
with records in the IPA database. Of these, 286 genes were
significantly up-regulated and 80 significantly down-regu-
lated in the CFS samples. Of the significantly up-regulated
genes, 105 genes showed that expression changed at least
2-fold and 16 genes at least 3-fold. The corresponding
numbers for the down-regulated genes are 25 and 3,
respectively. The ten most highly up-regulated genes and
the three most highly down-regulated genes are presented
in Table 1. The complete list of 366 genes (together with
the raw data) is accessible through GEO Series accession
number GSE14577.
To investigate the biological context of genes differentially
expressed in CFS patients, the IPA software was used, as
described in Methods. Figure 1 presents functional classes
associated with CFS patients. The network analysis
revealed the existence of 21 networks with the significant
score between 9 and 47, which together contain 349 out
of the 366 genes. The top three networks, containing 5 of
the top 10 up-regulated genes are presented in Figure 2
and include lactotransferrin (up-regulated 7.2-fold),
CXCR4 (up-regulated 3.6-fold), the integrins α2B and β3
(up-regulated 4.1 and 3.8-fold, respectively) and
defensin-α1 (up-regulated 6-fold).
Altered bio-systems in CFS
The gene signature of CFS highlighted changes in gene
expression in three main areas: oxidative stress, apoptosis
and viral-like immune dysfunction. These genes are sum-
marised in Table 2.
Oxidative stress
There is a large body of evidence from researchers in CFS
indicating that oxidative stress contributes to disease pro-
gression and resultant symptoms [25-29]. Our gene array
confirms evidence of oxidative stress (Table 2) with a large
change in the genes for prostaglandin-endoperoxide syn-
thase 1 and 2 (also known as COX-1 and -2). These
enzymes are responsible for the regulation of synthesis of
the pro-inflammatory mediators, prostaglandins. The
inducible form of COX-2 catalyses the conversion of ara-
chidonic acid to prostaglandins, the release of prosta-
noids, which sensitise peripheral nociceptor terminals
and produce localised pain hypersensitivity. COX-2 has
also been shown to be over-expressed at sites of inflam-
mation and in various tumours, with increased expression
of the major arachidonate metabolite, prostaglandin E2
(PGE2). COX-2 derived PGE2 is also known to increase
expression of decay-accelerating factor (DAF or CD55).
DAF is one of the key protective complement receptor
genes and an immune regulator, which is of interest as
DAF was up-regulated on our B chip. This is highly signif-
icant as regards immune suppression/subversion and cell
dissemination, which is discussed further in the section
on immune-modulation in CFS below. Furthermore, a
recent study by Maes et al. [8] showed that TNFα-stimu-
lated lymphocytes cultured from CFS patients resulted in
over-expression of NFkappaB (NFκB). COX-2 is responsi-
ble for multiple inflammatory actions, whilst NFκB is the
Table 1: Top 10 up-regulated genes (+) and top 3 down-regulated genes (-) in post-infectious CFS patients
Gene FC NCBI Accession Number
Top 10 up-regulated genes
Lactotransferrin (LTF) +7.2 NM_002343
Defensin α1 (DEFA1) +6.0 NM_004084
Charcot-Leyden Crystal protein (CLC) +5.6 NM_001828
Haemaglobin, gamma A (HBG1) +4.8 NM_000559
CEACAM8 +4.1 NM_001816
Integrin α2B (ITGA2B) +4.1 NM_000419
Haemaglobin, gamma G (HBG2) +3.9 NM_000184
Defensin α4 (DEFA4), corticostatin +3.9 NM_001925
Integrin β3 (ITGB3), CD61 +3.8 NM_000212
Chemokine (C-X-C) receptor 4 (CXCR4) +3.6 NM_001008540
Top 3 down-regulated genes
RPS26 -4.2 NM_001029
ZNF294 -3.8 AK023499
HLA-DQA1 -3.5 NM_022122BMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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High-level functional categories involved in this IPA analysis Figure 1
High-level functional categories involved in this IPA analysis. Y-axis displays -(log) significance. A) Top 10 biofunctions 
for CFS patients and B) total biofunctions for CFS patients. Taller bars are more significant than shorter bars. Functions are 
listed from most significant to least and the horizontal line denotes the cut-off for significance (p < 0.05).
Top 5 diseases/disorders associated with CFS patients. 
Name             p-value         No of Genes
Immunological Disease              2.72E-19 - 3.09E-03        80 
Connective Tissue Disorders             3.50E-18 - 2.06E-03        57 
Inflammatory Disease               3.50E-18 – 3.09E-03        78   
Skeletal and Muscular Disorders      3.50E-18 - 2.06E-03        69 
Cancer                    1.23E-09 - 3.37E-03        154 BMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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major upstream mechanism which regulates inflamma-
tory and oxidative stress mediators, such as pro-inflam-
matory cytokines, and COX-2 and inducible NOS (iNOS)
production. The over-expression of genes for oxidative
stress in CFS is also consistent with the up-regulation of
the haemoglobin genes, especially gamma haemoglobin,
which is usually only expressed in the foetus. Additional
up-regulated genes involved in oxidative stress were Leu-
kotriene B4, cytochrome P450, superoxide dysmutase and
the mono-oxygenases. Indirect evidence of SO2- attack
comes from the up-regulation of gamma, and alpha hae-
moglobin, especially gamma haemoglobin. This protein's
unique property of increased oxygen binding could be
induced as a result of oxidative attack.
Apoptosis
There is active apoptosis in the cells of patients with CFS
and consistent with this is the finding that many apopto-
sis-associated genes are up-regulated, including Caspase 1
(Table 2). Several factors may trigger apoptosis: cellular
damage, infection with a virus and homeostasis. The sig-
nal for apoptosis can be from within the cell, from sur-
rounding tissue or from a cell belonging to the immune
system. Among the top 100 up-regulated genes there is a
predominance of apoptosis-associated genes. Apoptotic
cells and their nuclei shrink and often fragment. They can
then be efficiently phagocytosed by macrophages or
neighbouring cells. From the gene array there is also evi-
dence of macrophage activation, with the up-regulation of
Toll-like receptor (TLR)-4 and TLR-8, and monocyte-to-
macrophage differentiation genes. As to exactly which
cells are undergoing apoptosis, theories abound. Kennedy
and co-workers have previously reported increases in neu-
trophil apoptosis in CFS [30]. It may be that it is these
groups of cells which are the targets of apoptosis, and our
array data certainly includes many genes related to neu-
trophils, as well as eosinophils.
Immune-modulation
Immune evasion is a well-documented mechanism by
which viruses, bacteria, parasites and cancer cells avoid
destruction by the host. Immune modulations can be var-
ied and complex. They include targeted disruption of T-
cell function, suppression of T-cell cytotoxic death recep-
tors, induction of apoptosis proteins, inhibition of innate
immune systems such as dendritic cell and natural killer
(NK) receptors. From this study, several genes associated
with the immune system are shown to be up-regulated in
patients with CFS, thus indicating possible functional
alterations (Table 2). Among those which have been iden-
tified are 2 genes belonging to the Major Histocompatibil-
ity Complex (MHC); HLA-DRB4 and HLA-DQB1 and
these genes encode β-chains on MHC class II molecules.
MHC class II molecules are found on antigen-presenting
cells, namely B-cells, dendritic cells and macrophages.
Differentially expressed gene networks Figure 2
Differentially expressed gene networks. Networks 
showing differentially up-regulated genes (red) and down-
regulated genes (green) in post-infectious CFS patients, 
whereby A) includes lactotransferrin (LTF, up-regulated 7.2-
fold), B) includes CXCR4 (up-regulated 3.6-fold) and C) 
includes the integrins α2B and β3 (up-regulated 4.1 and 3.8-
fold, respectively) and defensin-α1 (up-regulated 6-fold).
A
B
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Antigens associated with MHC class II are presented to
CD4+ cells, a subset of T-cells. Previous studies have iden-
tified perturbations in the expression of MHC class II
genes in patients with CFS. Steinau and co-workers indi-
cated a down-regulation of MHC class II molecules, how-
ever this work did not identify individual MHC class II
genes [31]. Subsequently, Smith et al. [32] indicated
increased expression of HLA-DQB1 and have also high-
lighted a number of other MHC genes altered in CFS. The
data presented in this current study therefore support
some of these findings, but also identify changes in the
expression of HLA-DRB4 in patients with CFS, which has
previously not been shown.
In addition to the MHC, within the top up-regulated
genes there are several genes encoding immune proteins
which belong to the innate immune system. Patients with
CFS have been suspected to have subtle immune dysfunc-
tion. Altered NK cell function in CFS patients has been
reported previously by Morrison et al. [33], and is verified
by the significant down-regulation of NK KIR receptors in
our gene array (Table 2). This data helps to confirm that
immunomodulatory gene expression is significantly dif-
ferent in CFS patients, as compared to healthy individuals.
Immune dysfunction appears to be present in patients
with CFS in the absence of any particular pathogen. The
classical Th1 to Th2 switch allows intracellular pathogens
to evade detection. As mentioned above, DAF is a regula-
tor of the complement system and is an immune regula-
tor. DAF appears to inhibit NK cells [34] and is known to
be one of the most potent activators of tumourigenesis/
viral dissemination. DAF is also known as a receptor for
certain viruses (including enteroviruses) and other micro-
organisms [35-37].
The immune modulation in post-Lyme disease fatigue is
remarkably similar to the gene signature presented here
for patients with CFS [38]. It is known that gene expres-
sion profiles of total mixed PBMC populations may mask
gene expression in subsets of cells [39]. This study, how-
ever, demonstrates very high expression of a number of
MHC class II genes normally observed in the minor pro-
portions of the PBMC, indicating significant changes
within these cell groups.
Up-regulated immune-related genes in patients include
lactotransferrin, defensin-α1 and integrins. Lactotransfer-
rin is an iron-binding protein responsible for immunolog-
ical reactions, while defensins are a family of microbicidal
and cytotoxic peptides released in response to viral and
bacterial infections. Defensins are also involved in the
anti-microbial defence of epithelial surfaces (i.e. respira-
tory and urinogenital tracts). Patients with CFS are known
to have increased susceptibility for infections and candi-
diasis is frequently reported [40].
Integrins are extracellular matrix proteins involved in cell
adhesion and also activate cytosolic signal cascades for
Table 2: Three altered bio-systems in CFS
Oxidative Stress Genes
Up-regulated
Prostaglandin Synthase: COX-1 and 2, haemoglobin gamma A and gamma G
Down-regulated
Glutathion-s-transferase
Apoptosis Genes: Up-regulated
Annexin -A3, -A5, Serine/threonine kinase 17b, Histones 1&2, Protein S (alpha), Serum deprivation response (Phosphatidylserine binding protein)
Caspase 1, TGFβ1
Death effector filament forming CED4-like apoptosis protein, Complement 3a receptor 1, Early growth response 1, TNF-A1P3, -RSF17, -SF4
Immune Dysfunction Genes (including markers of viral immuno-modulation/evasion)
Up-regulated
DAF (CD55) & CD46
Antigen processing via MHC class II (MHC II DP α1 and DR α)
IL-12, IL-13 & IL-6 biosynthesis
Down-regulated: The MHC-1 system including:
Natural Killer cell receptors (KIR)
TCR complex (T-cell receptors α, β, δ, γ)
NO production (up-regulation of arginase I & II)
Flavohaemoprotein B5
Leukocyte-derived arginine aminopeptidase (L-rap)BMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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RT-PCR assay and western blot analysis Figure 3
RT-PCR assay and western blot analysis. Detection of over-expression of defensin-α1 in CFS patients compared to nor-
mal healthy controls. A) 25 μl of each PCR product was electrophoresed through a 2.5% agarose gel, ethidium bromide stained 
and UV visualised. Lanes: L: DNA size ladder; 1–3: Healthy controls; 4–6: Patients with CFS. B) Western blot analysis. Each lane 
contained 2 × 105 PBMC and equivalent protein loading of all samples was confirmed by coomassie blue staining. Left-hand side 
of blot: 10 CFS patients; right-hand side of blot: 10 healthy controls.
A
                         L         1         2         3                4        5        6       L 
Lanes L: DNA size ladder;  1, 2, 3: healthy controls;  4, 5, 6: CFS patients 
B
Coomassie Protein Gel
RM
Defensin 1
CFS Patients ControlsBMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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cell growth and regulation. Arginase is a key enzyme con-
sidered to be active in immune modulation and is also
involved in NK cell function. Other notable up-regulated
genes include haemoglobins, especially foetal haemo-
globin, and this may suggest a response to increased oxi-
dative stress. Another family of up-regulated genes relate
to cellular apoptosis and serine-threonine kinase is a
member of brain kinase family of protein implicated in
neural apoptosis and formation of corpora amylacea. Of
the down-regulated genes, ribosomal protein gene and
zinc finger protein genes are involved in cell cycle and cel-
lular growth.
Validation of gene array data using RT-PCR and western 
blotting
Two members of the defensin gene family were found to
be amongst the most highly over-expressed genes in the
microarray; defensin-α1 and -α4. Defensins are a family
of cytotoxic peptides found in the microbicidal granules
of neutrophils and macrophages, and are released in
response to viral and bacterial infections. These proteins
are thus likely to play a role in phagocyte-mediated host
defence. As a result of the high defensin levels identified
in the microarray data, defensin-α1 was chosen for further
analysis. We aimed to confirm this data at the RNA and
protein level, using another cohort of blood samples from
10 CFS patients and 10 normal healthy controls. Oligonu-
cleotides and antibodies specific to defensin-α1 were used
to detect and compare changes at the RNA and protein
level using RT-PCR and western blotting, respectively. Fig-
ure 3A demonstrates up-regulation of defensin-α1 at the
RNA level in patients with CFS, when compared to nor-
mal healthy controls. Moreover, the immunoblot in Fig-
ure 3B demonstrates up-regulation of defensin-α1 protein
in all CFS patients (except for one), when compared to
controls that showed little or no defensin protein. Equal
loading was confirmed using coomassie blue staining.
Discussion
A comprehensive gene signature of non-psychiatric
patients with CFS has been generated by a whole-genome
microarray assay. The microarray data presented here
illustrates differences in gene expression across the human
genome between post-infectious, non-psychiatric male
patients with CFS and healthy controls. Analysis of the
gene signature of CFS suggests that three significant path-
ways are altered in patients: oxidative stress, apoptosis
and viral-like immune modulation. Previously, Gu et al.
[41] performed a 588-gene microarray whereby patients
with spondyloarthropathy, rheumatoid arthritis and pso-
riatic arthritis were compared to normal healthy subjects.
Of interest was their finding that expression of CXCR4
was unexpectedly high among all arthritis subjects. This
gene encodes a CXC chemokine receptor that is specific
for one ligand (stromal cell-derived factor-1), and CXCR4
is known to act with CD4 protein to support HIV entry
into cells. DNA microarray studies by Watanabe and co-
workers [42] demonstrated significant up-regulation of
the CXCR6 motif in ulcerative colitis patients, whilst other
work has indicated that the CXCL12/CXCR4 interaction is
involved in several inflammatory conditions, including
inflammatory bowel disease [43]. As a result, the finding
from our study (that CXCR4 was significantly up-regu-
lated in male CFS patients) indicates that this gene may
not be specific to CFS. It is noted, however, that in the CFS
studies by Kerr et al. (44, 45), CXCR4 was also up-regu-
lated.
The overall picture emerging from these results point to a
significant, albeit phenotypically subtle, perturbation of
function in relation to microbial defence, viral immuno-
surveillance and cell growth amongst patients with post-
infectious chronic fatigue. A possible criticism of the work
is that female patients were excluded. As already
explained, the primary reason for exclusion was to avoid
any confounding endocrine influence on gene signature.
Previous research has found few gender-related differ-
ences in terms of symptom severity. There was no gender
effect in a prospective cohort study of patients with post-
infectious fatigue attending primary care [44]. In general,
demographic, clinical and psychosocial factors do not dis-
tinguish men from women patients with CFS [45] and we
believe that the results of our research apply to CFS
patients of both genders.
Conclusion
Recent studies have attempted to determine the molecular
basis of CFS [46-49]. Table 3 illustrates overlapping genes
observed in CFS patients in our analysis and in previous
microarray studies (and one filter array study), by other
Table 3: Commonly overexpressed CFS genes between current study and previous microarray studies
Gow et al. (2009) Vernon et al. (2002) Kaushik et al. (2005) Fang et al. (2006) Kerr et al. (2008)
Dynactin1 Dynactin1
ARF1 ARF1
CEACAM family CEACAM family
Defensin family Defensin family
CXCR4 CXCR4
EGR1 EGR1
PRKAR1A PRKAR1ABMC Medical Genomics 2009, 2:38 http://www.biomedcentral.com/1755-8794/2/38
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researchers. Although there is some overlap, overall there
is a lack of correlation between different publications on
gene arrays to date. Whether this reflects different patient
populations and selection criteria remains unclear. It
must be borne in mind, however, that many mRNAs have
very short half-lives (i.e. less than 2 mins) and therefore
what is observed in the microarray is a snapshot in time
and may not necessarily reflect the chronic biological
process inherent of this condition. It is necessary, there-
fore, to validate the microarray data by more established
technologies such as RT-PCR, western blotting and ELISA,
and use wider populations of carefully selected patients to
validate the results.
The data presented here clearly illustrate important differ-
ences in gene expression between patients with post-infec-
tious CFS and healthy controls. While these differences in
gene signatures may offer a rational explanation for the
symptoms, and confirm that CFS is a true and biological
illness, gene microarray results do not imply that CFS is
primarily a genetic disorder. In addition, the research data
do not prove if differentially expressed genes are the pre-
disposing cause or downstream effect of CFS. We believe,
however, that the data presented here is an important first
step forward towards the goal of identifying putative
biomarkers to support the clinical diagnosis of CFS. Fur-
thermore, the biological pathways identified by the over-
expressed genes offer a rational understanding and possi-
ble explanation of the complex and often multi-systemic
nature of CFS, which is common and remains a poten-
tially disabling illness in search of an effective cure.
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